GSK unveils £1.9 billion savings drive to accelerate drug pipeline and rebuild cancer unit

British pharmaceutical company GSK announced a £1.9 billion ($2.52 billion) cost-savings programme on Tuesday, a strategic move designed to fund late-stage drug studies and accelerate development under the leadership of CEO Luke Miels. The initiative aims to rebuild the company’s cancer business ahead of critical patent losses that could impact its long-term financial targets.

The three-year savings drive is intended to simplify the organisation and reallocate capital and resources to support Miels’ promise of faster drug development. This comes as GSK seeks to offset impending patent expirations and maintain momentum toward its goal of achieving more than £40 billion in annual revenue by 2031. Under Miels, the company has increased its acquisition activity, including a record deal for Nuvalent in June, as part of its strategy to bolster its oncology portfolio.

GSK also reported that it had beaten second-quarter profit expectations, providing a positive backdrop to the announcement. The company pledged to invest £400 million in the UK, which includes the establishment of a new research and development centre. This commitment underscores the firm’s focus on domestic innovation even as it pursues global efficiency measures.

Miels stated in a release that the savings programme is critical to funding the late-stage portfolio and R&D efforts. By streamlining operations, the company intends to direct more resources toward high-priority studies, aiming to deliver tangible results to investors and patients alike. The market responded positively to the combined news of cost discipline, strong quarterly earnings, and domestic investment.

Shares in the company rose 4.2% by 1120 GMT following the announcement. The rally reflected investor confidence in Miels’ strategic direction, which balances aggressive growth targets with necessary structural reforms to ensure sustainable profitability in a competitive landscape.